


# Dx&Vx

## IR Letter

(Aug. 2024)



# Dx&Vx Business Roadmap



## Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

- Genomic Diagnostics
- In Vitro Diagnostics and CDMO
- Genomics CRO
- Companion Diagnostic Services (CliDex)



## Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

- Microbiome-based Therapeutic Adjuncts
- Nutrition Products
- Domestic and International CSO
- Functional Skincare/Personal Hygiene Products



## Drug Development

Our affiliate, Oxford Vacmedix, is preparing to initiate phase 1b clinical trials both domestically and internationally for its cancer vaccine, OVM-200, and our subsidiary Avixgen is about to start phase 2 trials for a dry eye treatment. Additionally, we have a pipeline of in-house developed drugs including microbiome-based therapies, mRNA cancer vaccines, oncology antibodies, and oral obesity treatments.

- Microbiome-based Drug Development
- ROP and mRNA Cancer Vaccines
- Cancer Antibody Drugs, Synthetic Organic Drugs
- Ophthalmic Disease Treatment Drugs



## Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

- K-hub
- Telemedicine Services
- AI-based Drug Development Platform
- Smart Diagnostic Devices

## Performance Summary for July 2024



### Accelerating the Development of Orally Administered Obesity Treatments



### Discovery of Immune-Related Functional Probiotics



### Participation in Asian and European Exhibitions

(Participation in Medlab & Asia Health and upcoming global medical device exhibitions)



### Expansion of Open Innovation

(Collaboration with GL PharmTech, Panacura, Youngjin Pharm, and POSTECH)



## Drug Development

### Accelerating the Development of Orally Administered Obesity Treatments

Our company has recently made significant progress in the development of orally administered GLP-1 obesity treatments. Utilizing AI technology for drug design, the compounds we've discovered have shown superior activity compared to existing controls in recent studies and are currently being optimized as new drug candidates.

We plan to expedite our international patent application schedule for these compounds, aiming to file within the third quarter of this year ahead of the originally planned timeline. Alongside early patent applications, we will continue to conduct additional studies, including animal testing, and actively pursue partnership negotiations considering various options such as co-development and early licensing out.

### Discovery of Immune-Related Functional Probiotics (Microbiome treatments and therapeutic aids)

Our microbiome research institute recently presented findings at the Korean Society of Microbial Biotechnology regarding probiotics involved in immune functions. This research confirmed that probiotics derived from human substances are effective in modulating and enhancing immunity, and can alleviate inflammation and hypersensitivity conditions.

Probiotics play a role in various areas including gut health, immunity, metabolism, and mental health. Based on these research results, we plan to commercialize various functional probiotics, and to dedicate efforts towards domestic and international patent applications and product development. Additionally, our company has secured two microbial strain patent technologies from our affiliated company, Coree Group, and is developing a range of products based on the microbiome.



## Medical Diagnostics

### Participation in Asian and European Exhibitions (Participation in Medlab & Asia Health)

Our company participated in the 'Medlab & Asia Health' exhibition held in Bangkok, Thailand, from July 10 to 12, where we engaged in discussions on partnership collaborations with global companies. This exhibition, the Southeast Asian version of 'Medlab Middle East,' is the largest event of its kind in Southeast Asia, featuring 350 booths from 30 countries and attracting over 19,000 visitors this year.

At the event, we showcased our key products and services, including 'GenomeCheck', 'CLIDEX', the KHUB telemedicine platform, and our cancer vaccines. Notably, 'GenomeCheck'—a non-invasive prenatal and neonatal genetic testing service—received high praise from many companies. We held meetings with approximately 100 companies, with significant interest shown by major pharmaceutical firms from Thailand, the Philippines, Malaysia, and Indonesia.

Through this exhibition, we plan to accelerate our business expansion in the global market, exploring numerous potential contracts. We aim to secure a leading position in the global market by showcasing our technological prowess and safety standards.



## Medical Diagnostics

### Participation in Asian and European Exhibitions (Selected as MEDICA 2024 Support Project and Will Participate in Global Medical Device Exhibition)

Our company has been selected to participate in the 'MEDICA 2024 K-Bio Sensor Pavilion' project organized by the Korea Semiconductor Research Consortium. We will be attending the 'MEDICA' medical device expo in Düsseldorf, Germany, this November. This expo is the world's largest of its kind, annually attracting over 5,000 exhibitors and more than 8,000 visitors from approximately 70 countries. At this event, we will unveil for the first time the mid-research results of our optical sensor system technology that utilizes biomarkers in urine. Additionally, we plan to simultaneously expand the global sales of our AI-based new drug development pipeline along with our customized genomic analysis and companion diagnostic services.



## Medical Diagnostics & Drug development

### Expansion of Open Innovation (Collaboration with GL PharmTech, Panacura, Youngjin Pharm, and POSTECH)

#### (Strategic MOU Signed with GL PharmTech)

Our company has entered into a strategic partnership agreement with GL PharmTech to expand new drug development and our pharmaceutical & biotech operations. Through this agreement, both companies will collaborate in multiple areas using our AI-based genomic analysis platform and the global network established across Korea and China. Our collaborative efforts will focus on new drug R&D, clinical trials, regulatory approvals, technology and finished product exports, as well as marketing of pharmaceutical and healthcare products.

#### (MOU Signed with Panacura for Development of Traditional Medicine Diagnostic Kits)

Our company has signed a Memorandum of Understanding (MOU) with Panacura, a developer of treatments based on traditional medicine materials, for the development and supply of traditional medicine diagnostic kits. Panacura, founded by Professor Jang Hyung-jin from Kyung Hee University College of Korean Medicine, is actively developing new drugs using herbal materials, as well as allergy diagnostic kits and rapid PCR diagnostic devices for traditional medicine. Through this agreement, both companies aim to jointly develop in vitro diagnostic devices for use in the field of traditional medicine. We plan to develop practical products by combining our 'CliDex' technology with Panacura's expertise in traditional medicine. Additionally, we will explore further business opportunities through Panacura's network of oriental hospitals and clinics.

#### (Strategic MOU Signed with Youngjin Pharm for Innovative Drug Development)

Our company has signed a strategic Memorandum of Understanding (MOU) with Youngjin Pharm to enhance the development of innovative drugs. Through this agreement, both companies will combine DxVx's AI-based drug design technology and clinical expertise with Youngjin Pharm's synthetic and evaluation capabilities to discover new candidate substances and accelerate the speed and success rate of new drug development. We will initially focus on selecting candidate substances for cancer treatments and plan to expand our research to various other indications. We are also keeping options open for additional joint research agreements based on the candidate substances secured and the results from preclinical studies.

#### (Research Service Agreement Signed with POSTECH for Bio-Material Parts Development)

DxVx has partnered with Pohang University of Science and Technology (POSTECH) to develop bio-material components over the next two years through joint research. This research service agreement builds on the successes of the 'LNP Process Development' conducted with POSTECH since last year, aiming to drive innovation in diagnostic technologies and commercialize key bio-material parts. Through this collaboration, we plan to develop cutting-edge technologies to lead the diagnostics industry and expect to unveil related new products in the second half of next year.

### Compliance Notice

This document is prepared solely for informational purposes to assist investors' understanding. It is based on data and information considered reliable, and has been diligently compiled; however, we do not guarantee its accuracy or completeness. Investment decisions should be made based on the investor's own judgment and responsibility. Under no circumstances can this material be used as legal evidence of liability for investment results.